264 related articles for article (PubMed ID: 25933967)
21. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Kruse V; Somers A; Van Bortel L; De Both A; Van Belle S; Rottey S
J Clin Pharm Ther; 2014 Jun; 39(3):259-65. PubMed ID: 24417304
[TBL] [Abstract][Full Text] [Related]
22. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.
Cabel L; Blanchet B; Thomas-Schoemann A; Huillard O; Bellesoeur A; Cessot A; Giroux J; Boudou-Rouquette P; Coriat R; Vidal M; Saidu NEB; Golmard L; Alexandre J; Goldwasser F
Fundam Clin Pharmacol; 2018 Feb; 32(1):98-107. PubMed ID: 29055166
[TBL] [Abstract][Full Text] [Related]
23. The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide.
Karbownik A; Szałek E; Sobańska K; Połom W; Grabowski T; Biczysko-Murawa A; Matuszewski M; Wolc A; Grześkowiak E
Eur J Drug Metab Pharmacokinet; 2015 Jun; 40(2):163-70. PubMed ID: 24676873
[TBL] [Abstract][Full Text] [Related]
24. Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: assay development and application to pharmacokinetic and tissue distribution studies.
Chen X; Wang Z; Liu M; Liao M; Wang X; Du H; Chen J; Yao M; Li Q
Biomed Chromatogr; 2015 May; 29(5):679-88. PubMed ID: 25294592
[TBL] [Abstract][Full Text] [Related]
25. Identifying 24 h variation in the pharmacokinetics of levofloxacin: a population pharmacokinetic approach.
Kervezee L; Stevens J; Birkhoff W; Kamerling IM; de Boer T; Dröge M; Meijer JH; Burggraaf J
Br J Clin Pharmacol; 2016 Feb; 81(2):256-68. PubMed ID: 26852745
[TBL] [Abstract][Full Text] [Related]
26. Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats.
Toyama Y; Ueyama J; Nomura H; Tsukiyama I; Saito H; Hisada T; Matsuura K; Hasegawa T
Anticancer Res; 2014 May; 34(5):2283-9. PubMed ID: 24778032
[TBL] [Abstract][Full Text] [Related]
27. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.
Bello CL; Sherman L; Zhou J; Verkh L; Smeraglia J; Mount J; Klamerus KJ
Anticancer Drugs; 2006 Mar; 17(3):353-8. PubMed ID: 16520665
[TBL] [Abstract][Full Text] [Related]
28. Sunitinib DDI with paracetamol, diclofenac, mefenamic acid and ibuprofen shows sex-divergent effects on the tissue uptake and distribution pattern of sunitinib in mice.
Tan SY; Wong MM; Tiew AL; Choo YW; Lim SH; Ooi IH; Modamio P; Fernández C; Mariño EL; Segarra I
Cancer Chemother Pharmacol; 2016 Oct; 78(4):709-18. PubMed ID: 27495788
[TBL] [Abstract][Full Text] [Related]
29. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
Speed B; Bu HZ; Pool WF; Peng GW; Wu EY; Patyna S; Bello C; Kang P
Drug Metab Dispos; 2012 Mar; 40(3):539-55. PubMed ID: 22180047
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.
Bello CL; Garrett M; Sherman L; Smeraglia J; Ryan B; Toh M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):699-707. PubMed ID: 20049443
[TBL] [Abstract][Full Text] [Related]
32. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D
Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of levofloxacin following oral administration of a generic levofloxacin tablet and intravenous administration to dogs.
Madsen M; Messenger K; Papich MG
Am J Vet Res; 2019 Oct; 80(10):957-962. PubMed ID: 31556716
[TBL] [Abstract][Full Text] [Related]
34. Drug-eluting beads loaded with antiangiogenic agents for chemoembolization: in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model.
Fuchs K; Bize PE; Dormond O; Denys A; Doelker E; Borchard G; Jordan O
J Vasc Interv Radiol; 2014 Mar; 25(3):379-87, 387.e1-2. PubMed ID: 24468044
[TBL] [Abstract][Full Text] [Related]
35. Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers.
Lee HK; DeVito V; Vercelli C; Tramuta C; Nebbia P; Re G; Kovalenko K; Giorgi M
Res Vet Sci; 2017 Jun; 112():26-33. PubMed ID: 28113087
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
37. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
de Bruijn P; Sleijfer S; Lam MH; Mathijssen RH; Wiemer EA; Loos WJ
J Pharm Biomed Anal; 2010 Mar; 51(4):934-41. PubMed ID: 19931354
[TBL] [Abstract][Full Text] [Related]
38. Quantitative determination of unbound levofloxacin by simultaneous microdialysis in rat pancreas after intravenous and oral doses.
Liu D; Xu S; Xiao H; Wang Z; Mao N; Zhou J; Liu R; Huang Y
J Pharm Pharmacol; 2014 Sep; 66(9):1215-21. PubMed ID: 24961375
[TBL] [Abstract][Full Text] [Related]
39. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs.
Landoni MF; Albarellos GA
J Vet Pharmacol Ther; 2019 Mar; 42(2):171-178. PubMed ID: 30302775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
